The Briefing Issue 08

I will come at this with my usual bias out loud: I love the needle. So it is worth sitting with a study that does not flatter it. A randomized trial took 80 people with linear scars and needled the scar itself, against a control group that got a needle placed away from the scar, with both groups also taped and warmed. The scar needling did what you would hope mechanically. Tissue compliance improved, the scar gave more under the same load. And the pain? No difference between the groups. The tissue changed and the symptom did not follow it out the door.

Read that next to a second paper from this month, a group of 64 shoulders where dry needling was added on top of a normal physical therapy program for supraspinatus tendinopathy. That group did better than therapy alone, across pain, disability, kinesiophobia, range, and even tendon thickness at three months. Not randomized, so hold it loosely, but the direction is clear.

Put the two together and you get the honest version of what the needle is. It is a real input. It changes tissue, and it makes a good program work better. It is not, by itself, the thing that changes the patient. That is exactly where the consensus puts it too. Candidacy first, dosing by irritability and tolerance, and the needle as a multiplier inside a plan, never the plan itself.

Here is the cleanest demonstration of the model I have seen in a while, and it is one patient. A man came in with left groin pain, pain down the inner thigh, and testicular pain. No stenosis, no herniation on the scan, nothing obvious to hang it on. What he had was an inflamed high-intensity zone in the L3-L4 disc, right in the intraforaminal corner where it could irritate the L3 nerve root. They put a diagnostic block on the L3 root. The groin pain, the thigh pain, and the testicular pain all left. Three months later the inflamed zone on the disc had shrunk on its own.

Sit with how far apart the pain and the problem were. The man felt it in his thigh and his testicle. The driver was a nerve root in his back. If you had treated where it hurt, you would have chased a groin and thigh pain and helped neither. This is the garden hose again. Step on the hose up here, the garden dies down there, and treating the garden does nothing.

We also got a small mechanism study worth stapling to it. In nine people with acute back pain, researchers put fine wires into the deep multifidus and recorded single motor units before and after a spinal manipulation. After the thrust, the firing steadied. The variability dropped without changing the firing rate. Tiny study, so do not oversell it, but it is a direct look at the segment talking to the muscle it feeds.

And if you want the sports version, a professional footballer spent a year being treated for recurrent hamstring strains that kept coming back even though the muscle looked healed on imaging. It was never the muscle. It was the sciatic nerve, bound at the proximal hamstring, and it settled with nerve mobilization rather than more hamstring rehab. The muscle was protecting the nerve, and the failure was not the nerve stressed beyond its load capacity but the muscle that can heal well.

Tennis elbow is one of my least favorite diagnoses, and it is not because it is hard. It is because the name tells you nothing about the cause. Somebody has lateral elbow pain, tender over the common extensor origin, and we call it a tendinopathy and treat the tendon. But ask the question we always ask: what is actually driving this, and is the driver where the pain is or somewhere upstream?

Most of these elbows never had an injury. There is no fall, no single moment. There is a weekend of gripping and lifting on tissue that was already low on capacity, and that low capacity often traces back to a C5 to C7 story the patient never mentions because their neck does not hurt. The elbow is where a longer setup finally showed up.

This month gave us a clean piece of the treatment side. A double-blind trial randomized 43 people with chronic tennis elbow to a real therapeutic dose of shockwave or a deliberately minimal dose, and gave both groups the same progressive loading program to do at home. Both got better. Pain fell about a quarter by six weeks, forty percent by three months, past half by six months. And there was no difference between the real dose and the token dose at any point. The shockwave dose did not carry the result. The loading and the time did.

That is the whole Root Cause Rounds lesson in one trial. The modality was the smallest decision in the room. What moved the needle was capacity, built slowly, on tissue that was under-built to start with. Keep it honest though. This is one trial of 43 people, and it does not say shockwave is useless. It says the dose you agonize over is not the lever you think it is.